References
- Liu X, Zhang Y, Tang L-L, et al. Characteristics of radiotherapy trials compared with other oncological clinical trials in the past 10 years. JAMA Oncol. 2018;4:1073–1079.
- Trone JC, Espenel S, Rehailia-Blanchard A, et al. Navigating the highlights of phase III trials: a watchful eye on evidence-based radiotherapy. Ann Oncol. 2017;28:2691–2697.
- Chargari C, Massard C, Deutsch E. Focus on the number of radiation oncology trials or on clinical relevance? JAMA Oncol. 2018;4:1791.
- Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700–712.
- Soares HP, Daniels S, Kumar A, et al. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ. 2004;328:22–24.
- Gilbert A, Ziegler L, Martland M, et al. Systematic review of radiation therapy toxicity reporting in randomized controlled trials of rectal cancer: a comparison of patient-reported outcomes and clinician toxicity reporting. Int J Radiat Oncol Biol Phys. 2015;92:555–567.
- Rivoirard R, Vallard A, Langrand-Escure J, et al. Thirty years of phase I radiochemotherapy trials: latest development. Eur J Cancer. 2016;58:1–7.
- Kemp R, Prasad V. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions and are they currently overused? BMC Med. 2017;15:134.
- Buyse M, Burzykowski T, Saad ED. The search for surrogate endpoints for immunotherapy trials. Ann Transl Med. 2018;6:231.
- Verma V, Simone CB, Werner-Wasik M. Acute and late toxicities of concurrent chemoradiotherapy for locally-advanced non-small cell lung cancer. Cancers. 2017;9:120.
- Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12:127–136.
- Spratt DE, Pei X, Yamada J, et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85:686–692.